{
  "title": "Vitamin D role in Alzheimer\u2019s, Parkinson\u2019s, and Huntington\u2019s",
  "slug": "vitamin-d-role-in-alzheimers-parkinsons-and-huntingtons",
  "aliases": [
    "/Vitamin+D+role+in+Alzheimers+Parkinsons+and+Huntingtons+-+March+2025",
    "/15884"
  ],
  "tiki_page_id": 15884,
  "date": "2025-03-12"
}

{{< toc >}}

---

#### Unlocking the Potential of Vitamin D: A Comprehensive Exploration of Its Role in Neurological Health and Diseases

Biology 2025, 14(3), 280; https://doi.org/10.3390/biology14030280

by Rehana Khatoon

Department of Medical Elementology and Toxicology, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi 110062, India

 **Table of Contents** 

<img src="https://d1bk1kqxc0sym.cloudfront.net/attachments/webp/toc-neuro-role.webp" alt="image" width="400">

 **Simple Summary** 

This review investigates the extended role of vitamin D beyond its traditional association with bone health, focusing on its influence on brain-related disorders. It highlights vitamin D’s involvement in regulating oxidative stress, inflammation, and anti-apoptotic pathways within the brain, with lower levels being linked to several neurological diseases. Vitamin D shows promise in reducing the risk or progression of neurodegenerative conditions through various protective mechanisms. This review added evidence from in vitro, in vivo, and clinical studies that demonstrate the positive effects of vitamin D across a range of different neurological disorders. In conclusion, vitamin D emerges as a potential neuroprotective agent with considerable relevance to human health.

 **Abstract** 

Vitamin D (VD), an indispensable micronutrient renowned for its pivotal role in bone health, is increasingly recognized as a frontline therapy for bone-related disorders owing to its involvement in maintaining calcium/phosphorus levels. Beyond these benefits, VD exhibits a modulatory impact on redox imbalance, inflammation, and anti-apoptotic pathways implicated in brain-related disorders. Recent findings reveal a notable decrease in VD and its receptor expression in the cerebrospinal fluid of individuals with brain diseases, indicating a positive association between VD levels and normal brain function. Moreover, emerging reports underscore VD’s potential in mitigating the pathophysiology of neurodegenerative diseases, including memory and motor impairments, mitochondrial dysfunction, and neuronal loss. Extensive in vitro and in vivo studies elucidate VD’s multifaceted neuroprotective mechanisms, effectively mitigating neuronal damage and ATP deprivation, thus reducing mortality and morbidity. This review comprehensively examines VD’s diverse attributes, encompassing antioxidative, anti-inflammatory, anti-apoptotic, and neurogenic effects. It provides contemporary insights into VD’s efficacious actions at appropriate doses and exposures across diverse neurological experimental models. Furthermore, the clinical relevance of VD in treating patients with neurological diseases is explored. Overall, this review contributes to the exploration of potential neuroprotective agents and holds promise for improving human health outcomes in the future.

 **<i class="fas fa-file-pdf" style="margin-right: 0.3em;"></i><a href="https://d1bk1kqxc0sym.cloudfront.net/attachments/pdf/vitamin-d-role-in-neurological-compresspdf.pdf">Download the PDF from VitaminDWiki </a>** 

---

#### The Role of Vitamin D in Huntington's Disease: From Deficiency to Therapeutic Potential [Perplexity AI March 2025](https://www.perplexity.ai/search/what-role-does-vitamin-d-play-YLFSMU2ISbyKg4xYIw9llA)

The complex relationship between  **Vitamin D**  and Huntington's disease (HD) has emerged as an important area of research in recent years. While Huntington's disease is primarily understood as a genetic disorder caused by an expanded HTT CAG repeat sequence, growing evidence suggests that  **Vitamin D**  deficiency may influence disease progression and that supplementation might offer therapeutic benefits. This report examines the prevalence of  **Vitamin D**  deficiency in HD patients, explores potential mechanisms through which  **Vitamin D**  affects neurological function in HD, reviews experimental evidence from animal studies, and discusses the potential for  **Vitamin D**  supplementation as a complementary therapeutic approach.

 **Prevalence and Significance of Vitamin D Deficiency in Huntington's Disease** 

 **Vitamin D**  deficiency appears to be remarkably common among individuals with Huntington's disease. A pioneering study by Chel et al. revealed that 89% of institutionalized patients with manifest  **HD**  had  **Vitamin D**  insufficiency, defined as serum 25(OH)D levels below 50 nmol/L [2](https://pmc.ncbi.nlm.nih.gov/articles/PMC3908964/) <sup>[5]</sup>. The mean serum 25(OH)D level in these  **HD**  patients was strikingly low at just 33 nmol/L (SD 15) [2](https://pmc.ncbi.nlm.nih.gov/articles/PMC3908964/). This prevalence of deficiency matches or even exceeds that observed in other neurodegenerative conditions such as  **Parkinson's disease**  <sup>[5]</sup> [7](https://pmc.ncbi.nlm.nih.gov/articles/PMC7453965/).

The significance of this deficiency extends beyond mere nutritional status. A positive association has been documented between serum 25(OH)D levels and functional capabilities in  **HD**  patients, specifically measured using the Functional Ambulation Classification (FAC) scores [2](https://pmc.ncbi.nlm.nih.gov/articles/PMC3908964/). This suggests that  **Vitamin D**  status may be linked to functional performance in individuals with  **HD** , though the causal relationship remains to be fully established.

Furthermore, individuals with Huntington's disease demonstrate alterations in bone metabolism that may be connected to  **Vitamin D**  insufficiency. Costa de Miranda et al. discovered that bone mineral density and T-scores were significantly lower in Huntington's patients compared to healthy controls <sup>[5]</sup>. Perhaps more tellingly, Goodman et al. detected significantly lower bone mineral density in high-risk individuals prior to the clinical manifestation of  **HD** , suggesting that bone metabolism alterations may begin early in the disease process <sup>[5]</sup>.

 **Mechanisms of Vitamin D Action in Huntington's Disease** 

Research, particularly in animal models, has identified several mechanisms through which  **Vitamin D**  might influence Huntington's disease pathophysiology. These mechanisms provide a scientific foundation for understanding how  **Vitamin D**  deficiency might contribute to disease progression and how supplementation might offer beneficial effects.

 **Neuroprotective Effects Through Anti-inflammatory Action** 

 **Vitamin D** 3 demonstrates substantial neuroprotective capacity in combating neuroinflammation, which is a key pathological feature of  **HD**  [3](https://pmc.ncbi.nlm.nih.gov/articles/PMC10776327/). In experimental studies,  **Vitamin D**  administration has been shown to downregulate the gene expression of key proinflammatory cytokines including tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) in  **HD**  mice [3](https://pmc.ncbi.nlm.nih.gov/articles/PMC10776327/). Additionally,  **Vitamin D**  intake exhibited a detrimental effect on nuclear factor kappa B (NF-κB) gene expression in the striatum, an area particularly affected in  **HD**  [3](https://pmc.ncbi.nlm.nih.gov/articles/PMC10776327/). This anti-inflammatory benefit is particularly relevant as elevated levels of pro-inflammatory cytokines like TNF-α and increased NF-κB activity are known to precede striatal neurodegeneration in  **HD**  [3](https://pmc.ncbi.nlm.nih.gov/articles/PMC10776327/).

 **Modulation of Oxidative Stress** 

Oxidative stress represents another fundamental pathological mechanism in Huntington's disease.  **Vitamin D** 3 supplementation has demonstrated antioxidant effects in  **HD**  mice, decreasing the gene expression of oxidative stress markers such as catalases (Cat) and glutathione peroxidase (GpX4) [3](https://pmc.ncbi.nlm.nih.gov/articles/PMC10776327/) [4](https://pubmed.ncbi.nlm.nih.gov/35413386/). This suggests that  **Vitamin D**  may help reduce the burden of oxidative damage that contributes to neuronal loss in  **HD** . The reduction in oxidative stress markers following  **Vitamin D**  supplementation correlates with improved outcomes in experimental models, suggesting this may be an important pathway through which  **Vitamin D**  exerts beneficial effects [3](https://pmc.ncbi.nlm.nih.gov/articles/PMC10776327/).

 **Enhancement of Cholinergic Neurotransmission** 

A particularly interesting mechanism involves  **Vitamin D** 's effects on cholinergic neurotransmission, which is often compromised in neurodegenerative conditions.  **Vitamin D** 3 administration has been shown to attenuate acetylcholinesterase (AChE) activity in both the cortex and striatum of  **HD**  mice [3](https://pmc.ncbi.nlm.nih.gov/articles/PMC10776327/). Since AChE breaks down acetylcholine, its inhibition by  **Vitamin D**  potentially restores acetylcholine levels, enhancing cholinergic signaling. Cholinergic deficiency and increased AChE levels have been previously linked to memory impairment in experimental models of  **HD** , making this mechanism particularly relevant to cognitive symptoms [3](https://pmc.ncbi.nlm.nih.gov/articles/PMC10776327/).

 **Upregulation of Neurotrophic Factors** 

Perhaps one of the most promising mechanisms involves  **Vitamin D** 's ability to enhance the expression of crucial neurotrophic factors. In experimental  **HD**  models,  **Vitamin D**  supplementation led to significant enhancement in the expression of key neurotrophic factors including brain-derived neurotrophic factor (BDNF) and nerve-growth factor (NGF) [3](https://pmc.ncbi.nlm.nih.gov/articles/PMC10776327/) [4](https://pubmed.ncbi.nlm.nih.gov/35413386/). These factors are essential for neuronal survival and function, and their depletion is implicated in  **HD**  pathogenesis. The  **Vitamin D**  receptor (VDR) appears to mediate this upregulation, activating neuronal survival pathways that may help preserve neurons in  **HD**  [3](https://pmc.ncbi.nlm.nih.gov/articles/PMC10776327/).

 **Modulation of Immune System Markers** 

Emerging evidence suggests  **Vitamin D**  also influences neuroinflammation through effects on immune receptors. Prolonged administration of  **Vitamin D** 3 has shown neuroprotective effects by decreasing the gene expression of the immune receptor T-cell receptor beta (TCR-β) subunit in both the cortex and striatum of  **HD**  mice [3](https://pmc.ncbi.nlm.nih.gov/articles/PMC10776327/). This is significant because enhanced expression of immune receptors is increasingly recognized as playing a role in neurodegenerative disorders.

 **Evidence from Animal Studies on** Vitamin D **Supplementation** 

Experimental studies in animal models of Huntington's disease have provided compelling evidence for the potential benefits of  **Vitamin D**  supplementation. These studies have examined various outcomes including survival, motor function, and neurobiological markers.

 **Impact on Survival** 

Perhaps the most striking finding comes from a study demonstrating that high-dose  **Vitamin D** 3 supplementation significantly increased the lifespan of transgenic  **HD**  animals. While vehicle-supplemented  **HD**  mice survived for a median of 73 days (range 67-94 days), those receiving  **Vitamin D** 3 supplementation lived substantially longer with a median survival of 101 days (range 74-109 days), representing a statistically significant improvement (p=0.048) [1](https://pubmed.ncbi.nlm.nih.gov/27685770/). This prolongation of survival, even without measurable improvements in motor performance in that particular study, suggests that  **Vitamin D**  may exert fundamental neuroprotective effects that enhance overall resilience in  **HD**  [1](https://pubmed.ncbi.nlm.nih.gov/27685770/).

 **Effects on Motor Function and Movement** 

The impact of  **Vitamin D**  on motor function in  **HD**  appears nuanced across different studies. Manjari et al. demonstrated that  **Vitamin D**  supplementation at a dose of 500 IU/kg/day rescued locomotor dysfunction and neuromuscular impairment in a 3-nitropropionic acid (3-NP) induced  **HD**  mouse model [4](https://pubmed.ncbi.nlm.nih.gov/35413386/). The same research showed that  **Vitamin D**  supplementation induced survival signals, diminished oxidative stress, and reduced movement and motor dysfunction in these  **HD**  mice [4](https://pubmed.ncbi.nlm.nih.gov/35413386/). However, another study by Klivényi et al. indicated that while  **Vitamin D** 3 significantly increased lifespan, it had no measurable effect on the motor performance of transgenic mice [1](https://pubmed.ncbi.nlm.nih.gov/27685770/). These seemingly contradictory findings may relate to differences in animal models, dosing regimens, or assessment methods, highlighting the need for additional research.

 **Neurobiological Effects** 

At the neurobiological level,  **Vitamin D**  supplementation shows promising effects on brain function in  **HD**  models. Studies indicate that  **Vitamin D**  administration provides protective effects in maintaining both cortical and striatal functions in  **HD**  mice [3](https://pmc.ncbi.nlm.nih.gov/articles/PMC10776327/). As mentioned previously,  **Vitamin D**  significantly attenuated acetylcholinesterase activity in both the cortex and striatum, suggesting improved cholinergic neurotransmission which is essential for cognitive function [3](https://pmc.ncbi.nlm.nih.gov/articles/PMC10776327/). The observed enhancements in neurotrophic factor expression and reductions in oxidative stress markers after  **Vitamin D**  supplementation further support its beneficial neurobiological effects [3](https://pmc.ncbi.nlm.nih.gov/articles/PMC10776327/) [4](https://pubmed.ncbi.nlm.nih.gov/35413386/).

 **Therapeutic Potential and Clinical Implications** 

Despite the promising experimental evidence, the translation of these findings into clinical applications for Huntington's disease patients remains in early stages.

 **Current State of Clinical Research** 

Notably, despite the evidence of widespread  **Vitamin D**  deficiency in  **HD**  patients and promising results from animal studies, there are currently no completed supplementation studies in patients with Huntington's disease reported in the available search results [7](https://pmc.ncbi.nlm.nih.gov/articles/PMC7453965/). Experts in the field have emphasized that "investigations of disease-specific or general effects of  **Vitamin D**  administration, be it substitutional or prophylactic, should be of great interest" [7](https://pmc.ncbi.nlm.nih.gov/articles/PMC7453965/). This highlights a significant gap in the research that needs to be addressed through well-designed clinical trials.

 **Potential as a Complementary Therapy** 

The collective findings suggest that  **Vitamin D**  may serve as a valuable supplementary treatment in Huntington's disease management. Multiple researchers have proposed that " **Vitamin D**  may be an effective supplementary treatment to beneficially influence clinical features of Huntington's disease" [1](https://pubmed.ncbi.nlm.nih.gov/27685770/). However, it remains unclear whether  **Vitamin D**  exerts its effects through a specific neuroprotective mechanism or through a more general corroborative effect [1](https://pubmed.ncbi.nlm.nih.gov/27685770/). Either way, given the established safety profile of  **Vitamin D**  supplementation when appropriately dosed, and the high prevalence of deficiency in  **HD**  patients, addressing  **Vitamin D**  status appears to be a reasonable clinical consideration.

 **Dosage and Administration Considerations** 

While optimal dosing regimens for  **Vitamin D**  in  **HD**  have not been established in human studies, the animal research provides some guidance. In mouse models, doses of 500 IU/kg/day have shown beneficial effects [3](https://pmc.ncbi.nlm.nih.gov/articles/PMC10776327/) [4](https://pubmed.ncbi.nlm.nih.gov/35413386/). However, direct extrapolation to human dosing requires caution. In general,  **Vitamin D**  sufficiency is considered when serum levels are above 50 nmol/L, with levels below 30 nmol/L indicating deficiency [9](https://hospiceofhuntington.org/get-help/tips-from-the-dietitian/vitamin-d-deficiency/). Supplementation approaches would likely need to be tailored based on individual baseline levels, with the goal of achieving normal physiological ranges rather than supraphysiological concentrations.

 **Comparison with Other Nutritional Approaches in HD** 

 **Vitamin D**  is not the only nutritional intervention that has been investigated for potential benefits in Huntington's disease. Understanding how it compares with other approaches provides additional context for its potential role.

 **Vitamin E (Alpha-tocopherol)** 

Alpha-tocopherol (vitamin E) has been studied for  **HD**  based on the hypothesis that it reduces oxyradical damage to cell membranes [10](https://pubmed.ncbi.nlm.nih.gov/8526244/). A prospective, double-blind, placebo-controlled study found that while treatment with d-alpha-tocopherol had no overall effect on neurologic and neuropsychiatric symptoms, post hoc analysis revealed a significant therapeutic effect on neurologic symptoms for patients early in the disease course [10](https://pubmed.ncbi.nlm.nih.gov/8526244/). This parallels some findings with  **Vitamin D** , suggesting that antioxidant therapies may be more effective in early stages of  **HD** .

 **Thiamine (Vitamin B1) and Biotin** 

Recent research suggests another potential nutritional deficiency in  **HD** : thiamine (vitamin B1). Studies indicate a thiamine deficiency in the  **HD**  brain, with the possibility that  **HD**  patients might benefit from thiamine and/or biotin supplementation therapy [11](https://dnascience.plos.org/2021/09/30/does-a-vitamin-deficiency-in-the-brain-lie-behind-huntingtons-disease/). This highlights that multiple nutritional factors may contribute to  **HD**  pathophysiology, potentially offering complementary therapeutic approaches.

 **Conclusion** 

The evidence indicates that  **Vitamin D**  plays a potentially significant role in Huntington's disease through multiple mechanisms including anti-inflammatory effects, antioxidant properties, enhancement of cholinergic neurotransmission, upregulation of neurotrophic factors, and modulation of immune system markers. The remarkably high prevalence of  **Vitamin D**  deficiency in  **HD**  patients (89%) suggests this may be more than coincidental and could contribute to disease progression.

Animal studies provide compelling evidence that  **Vitamin D**  supplementation can extend survival, improve motor function, and favorably modify neurobiological markers in  **HD**  models. However, the translation of these findings into clinical practice requires further investigation through well-designed human trials. Until such studies are completed, addressing  **Vitamin D**  deficiency in  **HD**  patients represents a reasonable clinical consideration given its established safety profile and the high prevalence of insufficiency in this population.

Future research should focus on determining optimal supplementation regimens, identifying which patients might benefit most from  **Vitamin D**  therapy, and exploring potential synergies with other treatments. Combination approaches that address multiple nutritional deficiencies including  **Vitamin D** , vitamin E, thiamine, and biotin might offer more comprehensive benefits than single-nutrient interventions. As our understanding of the complex interplay between nutrition and neurodegeneration continues to evolve,  **Vitamin D**  appears to be an increasingly important piece of the therapeutic puzzle for Huntington's disease.

 **Citations:** 

1. [https://pubmed.ncbi.nlm.nih.gov/27685770/](https://pubmed.ncbi.nlm.nih.gov/27685770/)

1. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3908964/](https://pmc.ncbi.nlm.nih.gov/articles/PMC3908964/)

1. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10776327/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10776327/)

1. [https://pubmed.ncbi.nlm.nih.gov/35413386/](https://pubmed.ncbi.nlm.nih.gov/35413386/)

1. [https://tremorjournal.org/articles/74/files/submission/proof/74-1-3326-2-10-20200825.pdf](https://tremorjournal.org/articles/74/files/submission/proof/74-1-3326-2-10-20200825.pdf)

1. [https://onlinelibrary.wiley.com/doi/10.1155/2015/192747](https://onlinelibrary.wiley.com/doi/10.1155/2015/192747)

1. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7453965/](https://pmc.ncbi.nlm.nih.gov/articles/PMC7453965/)

1. [https://jamanetwork.com/journals/jama/fullarticle/2532012](https://jamanetwork.com/journals/jama/fullarticle/2532012)

1. [https://hospiceofhuntington.org/get-help/tips-from-the-dietitian/vitamin-d-deficiency/](https://hospiceofhuntington.org/get-help/tips-from-the-dietitian/vitamin-d-deficiency/)

1. [https://pubmed.ncbi.nlm.nih.gov/8526244/](https://pubmed.ncbi.nlm.nih.gov/8526244/)

1. [https://dnascience.plos.org/2021/09/30/does-a-vitamin-deficiency-in-the-brain-lie-behind-huntingtons-disease/](https://dnascience.plos.org/2021/09/30/does-a-vitamin-deficiency-in-the-brain-lie-behind-huntingtons-disease/)

1. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6121649/](https://pmc.ncbi.nlm.nih.gov/articles/PMC6121649/)

1. [https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2024.1333217/full](https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2024.1333217/full)

1. [https://tremorjournal.org/articles/10.5334/tohm.74](https://tremorjournal.org/articles/10.5334/tohm.74)

1. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8533313/](https://pmc.ncbi.nlm.nih.gov/articles/PMC8533313/)

1. [https://pubmed.ncbi.nlm.nih.gov/24516688/](https://pubmed.ncbi.nlm.nih.gov/24516688/)

1. [https://www.mdpi.com/2227-9059/9/10/1284](https://www.mdpi.com/2227-9059/9/10/1284)

1. [https://www.imrpress.com/journal/JIN/21/6/10.31083/j.jin2106155/htm](https://www.imrpress.com/journal/JIN/21/6/10.31083/j.jin2106155/htm)

1. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10674993/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10674993/)

1. [https://en.hdbuzz.net/324](https://en.hdbuzz.net/324)

1. [https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2796088](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2796088)